Tin tức & Cập nhật

IV ginkgo may boost brain recovery after stroke

13 Feb 2024 bởi

In a placebo-controlled trial, active components of Ginkgo biloba given intravenously for 14 days helps improve cognitive recovery among patients following an acute ischaemic stroke.

IV ginkgo may boost brain recovery after stroke

13 Feb 2024

Prophylactic oropharyngeal surfactant does little to reduce intubation risk in preemies

12 Feb 2024

Administration of surfactant into the oropharynx of neonates delivered before 29 weeks of gestation falls short of reducing the rate of intubation in the first 120 hours of life, according to the results of POPART*.

Prophylactic oropharyngeal surfactant does little to reduce intubation risk in preemies

12 Feb 2024

Sibeprenlimab shows promise in IgA nephropathy

11 Feb 2024

In the treatment of patients with IgA nephropathy, the use of sibeprenlimab, a humanized IgG2 monoclonal antibody that binds to and neutralizes a proliferation-inducing ligand (APRIL), appears to lead to a significant reduction in proteinuria, according to a phase II trial.

Sibeprenlimab shows promise in IgA nephropathy

11 Feb 2024

Glucagon/GLP-1 receptor dual agonist for weight loss shows therapeutic potential

11 Feb 2024

The glucagon/GLP-1 receptor dual agonist survodutide appears to be safe and induce weight loss in individuals with obesity, according to data from a phase II dose-finding trial.

Glucagon/GLP-1 receptor dual agonist for weight loss shows therapeutic potential

11 Feb 2024

Novel anti-influenza A virus inhibitor works in patients with uncomplicated flu infection

10 Feb 2024

Treatment with the anti-influenza A virus inhibitor onradivir is safe and leads to symptom improvement and viral load reduction in adults with uncomplicated influenza infection, according to data from a phase II trial.

Novel anti-influenza A virus inhibitor works in patients with uncomplicated flu infection

10 Feb 2024

Erdafitinib on par with pembrolizumab in metastatic urothelial cancer

07 Feb 2024

Treatment with erdafitinib or pembrolizumab results in similar median overall survival (OS) in pretreated patients with advanced or metastatic urothelial cancer (mUC) with select fibroblast growth factor receptor (FGFR) alterations (FGFRalt), a study has shown. Safety results are also comparable to the known profiles for both regimens in this patient population.

Erdafitinib on par with pembrolizumab in metastatic urothelial cancer

07 Feb 2024

Elevated INR predicts mortality in DOAC-treated patients

06 Feb 2024

Among hospitalized patients treated with direct oral anticoagulants (DOACs), an elevated international normalized ratio (INR) upon admission may spell an increased risk for in-hospital death or mortality during the first year following hospitalization, suggests a study.

Elevated INR predicts mortality in DOAC-treated patients

06 Feb 2024

Idiopathic Parkinson’s disease: Which dopamine agonist is associated with lower risk of impulse control–related behavioural disorders?

06 Feb 2024 bởi

In Chinese patients with idiopathic Parkinson’s disease (IPD) on their first dopamine agonist (DA) monotherapy for >6 months, bromocriptine is associated with a lower risk of impulse control–related behavioural disorders (ICRDs) compared with pramipexole and ropinirole, an observational cohort study in Hong Kong has shown. Rotigotine demonstrated a trend towards lower ICRD risk than the latter two DAs.

Idiopathic Parkinson’s disease: Which dopamine agonist is associated with lower risk of impulse control–related behavioural disorders?

06 Feb 2024

Antenatal low-dose aspirin exposure has no bearing on neurodevelopmental outcomes of offspring

06 Feb 2024

Babies born to mothers who were exposed to low-dose aspirin during pregnancy do not appear to have altered neurodevelopmental outcomes at age 3 years, according to a study.

Antenatal low-dose aspirin exposure has no bearing on neurodevelopmental outcomes of offspring

06 Feb 2024

Ketamine a viable alternative to morphine for out-of-hospital traumatic pain

05 Feb 2024

Ketamine is noninferior to morphine in terms of providing pain relief in patients with out-of-hospital traumatic pain, according to the results of the KETAMORPH* study.

Ketamine a viable alternative to morphine for out-of-hospital traumatic pain

05 Feb 2024

Tin tức & Cập nhật

Lọc theo Chuyên ngành:

Chuyên ngành:

IV ginkgo may boost brain recovery after stroke

IV ginkgo may boost brain recovery after stroke

Prophylactic oropharyngeal surfactant does little to reduce intubation risk in preemies

Prophylactic oropharyngeal surfactant does little to reduce intubation risk in preemies

Sibeprenlimab shows promise in IgA nephropathy

Sibeprenlimab shows promise in IgA nephropathy

Glucagon/GLP-1 receptor dual agonist for weight loss shows therapeutic potential

Glucagon/GLP-1 receptor dual agonist for weight loss shows therapeutic potential

Novel anti-influenza A virus inhibitor works in patients with uncomplicated flu infection

Novel anti-influenza A virus inhibitor works in patients with uncomplicated flu infection

Erdafitinib on par with pembrolizumab in metastatic urothelial cancer

Erdafitinib on par with pembrolizumab in metastatic urothelial cancer

Elevated INR predicts mortality in DOAC-treated patients

Elevated INR predicts mortality in DOAC-treated patients

Idiopathic Parkinson’s disease: Which dopamine agonist is associated with lower risk of impulse control–related behavioural disorders?

Idiopathic Parkinson’s disease: Which dopamine agonist is associated with lower risk of impulse control–related behavioural disorders?

Antenatal low-dose aspirin exposure has no bearing on neurodevelopmental outcomes of offspring

Antenatal low-dose aspirin exposure has no bearing on neurodevelopmental outcomes of offspring

Ketamine a viable alternative to morphine for out-of-hospital traumatic pain

Ketamine a viable alternative to morphine for out-of-hospital traumatic pain